Osteoporosis - secondary prevention including strontium ranelate: final appraisal determination 2

After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women and submitted it to the Institute.

The FAD has been sent to the formal consultees for this appraisal who commented on the economic model. They have 15 working days to consider whether they wish to appeal against it.

Please note that the appeal period for this appraisal will close at 5pm on 21 December 2009.

This page was last updated: 30 March 2010